

**The role of glucocorticoid-dependent mechanism in the
pathogenesis of experimental acute pancreatitis**

Ph.D.Thesis

Attila Paszt M.D.

Szeged

2009

**The role of glucocorticoid-dependent mechanism in the
pathogenesis of experimental acute pancreatitis**

Ph.D.Thesis

Attila Paszt M.D.

Department of Surgery, Faculty of Medicine
University of Szeged
Szeged, Hungary

2009

CONTENTS

LIST OF ARTICLES AND ABSTRACTS RELATED TO THE SUBJECT OF THE DISSERTATION	3
ABBREVIATIONS	5
1. INTRODUCTION	6
1.1. Pathophysiology of acute pancreatitis	6
1.1.1. Diagnosis	6
1.1.2. Prognosis	7
1.1.3. Therapy	8
1.2. Scientific background	9
1.3. Aims	10
2. MATERIALS AND METHODS	11
2.1. Experimental protocols	11
2.1.1. Study I	11
2.1.2. Study II	12
2.2. Surgical preparation	12
2.2.1. Experimental acute pancreatitis	12
2.2.2. Collection and analysis of plasma samples	13
2.3. Measurements	13
2.3.1. Survival analysis	13
2.3.2. Pancreatic weight / body weight (pw/bw) ratio determination	13
2.3.3. Plasma amylase activity	13
2.3.4. Cytokine assays	13
2.3.4.1. Plasma IL-6 activity	13
2.3.4.2. Macrophage migration inhibitory factor activity	14
2.3.5. Assay of inflammatory mediator in pancreatic tissue: Nuclear transcription factor κ B analysis	14
2.3.6. Reporter cell lines	14
2.3.6.1. Media	15
2.3.6.2. Luciferase assay	15
2.3.7. Analysis of liver and lung tissue samples	15
2.3.7.1. Myeloperoxidase activity	15
2.3.7.2. ATP measurement	15

2.3.8.	Histology	16
2.3.9.	Light microscopy.....	17
2.3.10.	Data analysis and statistical comparisons.....	17
3. RESULTS	18
3.1.	Study I.....	18
3.1.1.	Survival analysis.....	18
3.1.2.	Pancreatic weight / body weight ratio.....	18
3.1.3.	Plasma amylase activity.....	19
3.1.4.	Plasma IL-6 activity.....	20
3.1.5.	Liver and lung MPO activity.....	21
3.1.6.	Liver and lung ATP activity	22
3.1.7.	Gross pathology.....	23
3.1.8.	Histology.....	24
3.2.	Study II	24
3.2.1.	Pancreatic weight / body weight ratio	24
3.2.2.	Plasma amylase activity.....	25
3.2.3.	Plasma IL-6 activity.....	26
3.2.4.	Plasma MIF level.....	26
3.2.5.	Proinflammatory cytokines in the pancreas.....	27
3.2.6.	Gross pathology.....	28
3.2.7.	Histology.....	29
4. DISCUSSION	32
5. SUMMARY AND NEW FINDINGS	38
6. ACKNOWLEDGEMENTS	40
7. REFERENCES	41
8. ANNEX	47

**LIST OF ARTICLES AND ABSTRACTS RELATED TO THE SUBJECT OF THE
DISSERTATION**

List of full papers related to the subject of the dissertation:

I. **Paszt Attila**, Rakonczay Zoltán, Kaszaki József, Szentpáli Károly, Wolfard Antal, Tiszlavicz László, ifj. Lázár György:

Glükokortikoid hormonok által szabályozott mechanizmusok szerepe kísérletes akut pancreatitis lefolyásában. *Magy. Seb.* 2003; 56:185-92.

II. **Paszt Attila**, Takács Tamás, Rakonczay Zoltán, Kaszaki József, Wolfard Antal, Tiszlavicz László, Lázár György, Duda Ernő, Szentpáli Károly, Czakó László, Boros Mihály, Balogh Ádám, ifj. Lázár György:

The role of the glucocorticoid-dependent mechanism in the progression of sodium taurocholate-induced acute pancreatitis in the rat. *Pancreas* 2004; 29:75-82.

III. **Paszt Attila**, Éder Katalin, Szabolcs Annamária, Tiszlavicz László, Lázár György, Duda Ernő, Takács Tamás, ifj. Lázár György:

Effects of glucocorticoid agonist and antagonist on the pathogenesis of L-arginine-induced acute pancreatitis in rat. *Pancreas* 2008; 36:369-76.

List of abstracts related to the subject of the dissertation:

Paszt Attila, Farkas Gyula, Nagy Erzsébet:

Importance of radiological and surgical treatment following necrotising pancreatitis. European Congress of the International Hepato-Pancreato-Biliary Association (IHPBA), Budapest, 1999. *Dig. Surg.* 1999; 16:(Suppl. 1) 97.

Paszt Attila, ifj. Lázár György, Takács Tamás, ifj. Rakonczay Zoltán, Varga János, Lázár György, Duda Ernő, Tiszlavicz László, Kaszaki József, Lonovics János, Farkas Gyula, Balogh Ádám, Boros Mihály:

The role of glucocorticoid-dependent mechanism in the progression of sodium-taurocholate-induced acute pancreatitis in the rat.

Congress of the European Society for Surgical Research, Santiago de Compostela, 2001. *Eur. Surg. Res.* 2001; 33:124.

Paszt Attila, Rakonczay Zoltán, Kaszaki József, Szentpáli Károly, Wolfard Antal, Tiszlavicz László, ifj. Lázár György:

Glucocorticoid hormonok által szabályozott mechanizmusok szerepe kísérletes akut pancreatitis lefolyásában.

Magyar Sebész Társaság Kísérletes Sebész Szekció XIX. Kongresszusa, Siófok, 2003.
Magy. Seb. 2003; 56:152.

Paszt Attila, Takács Tamás, Rakonczay Zoltán, Kaszaki József, Tiszlavicz László, Lázár György, Duda Ernő, Szentpáli Károly, Farkas Gyula, Lonovics János, Boros Mihály, Balogh Ádám, ifj. Lázár György:

The role of glucocorticoid dependent mechanisms in the experimental acute pancreatitis
45th Annual Meeting of the Hungarian Society of Gastroenterology, Balatonaliga, 2003.
Z. Gastroenterol. 2003; 41:90.

Paszt Attila, Szabolcs Annamária, Tiszlavicz László, Duda Ernő, Takács Tamás, ifj.Lázár György:

Glucocorticoid dependent mechanisms in the progression of L-arginine-induced acute pancreatitis in rats: the role of NF- κ B activation.

Congress of the European Society for Surgical Research, Konya, 2005.
Eur. Surg. Res. 2005; 37:70.

Paszt Attila, Szabolcs Annamária, Tiszlavicz László, Duda Ernő, Takács Tamás, ifj.Lázár György:

Glucocorticoid hormonok hatása L-arginin indukálta kísérletes akut pancreatitisben: az NF- κ B aktiváció szabályozó mechanizmusai.

Magyar Sebész Társaság Kísérletes Sebész Szekció XX. Kongresszusa, Hajdúszoboszló, 2005. *Magy. Seb.* 2005; 58:270.

ABBREVIATIONS

AP:	Acute pancreatitis
APACHE:	Acute physiology and chronic health evaluation
Bw:	Body weight
CRP:	C-reactive protein
CT:	Computer tomography
TNF- α :	Tumor necrosis factor-alpha
IL:	Interleukin
DEX:	Dexamethasone
HYD:	Hydrocortisone
I κ B α :	Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
Ip:	intraperitoneal
L-Arg:	L-arginine
RU:	RU-38486
MIF:	Macrophage migration inhibitory factor
MP:	Methylprednisolone
APD:	Acute pancreatitis dexamethasone
APH:	Acute pancreatitis hydrocortisone
APRU:	Acute pancreatitis RU-38486
Sc:	subcutaneously
ShamDEX:	Sham dexamethasone
ShamHYD:	Sham hydrocortisone
ShamMRU:	Sham RU-38486
Pw/bw:	Pancreatic weight / body weight
ATP:	Adenosine triphosphate
MPO:	Myeloperoxidase
APMP:	Acute pancreatitis methylprednisolone
MTT:	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NF- κ B	Nuclear transcription factor kappa B
LPS:	Lipopolysaccharide
FCS:	Fetal calf serum

1. INTRODUCTION

1.1. Pathophysiology of acute pancreatitis

The spectrum of acute pancreatitis (AP) ranges from a mild edematous disease to a severe necrotizing process which is usually accompanied by local or systemic complications. Although the exact mechanisms which trigger the inflammatory and necrotizing processes are not completely understood, it is generally accepted that autodigestion and an acute inflammatory response of the pancreas via the activation of proteases of the pancreas and activated leukocytes play important roles in the pathogenesis of AP. This amplified cytokine response is one of the most important pathophysiological factors in the development of complications, and especially in the progression of a limited local pancreatic inflammation into a potentially dangerous systemic inflammatory reaction termed multiple organ dysfunction syndrome. The incidence of AP has increased in the past two decades. The incidence of first-time attacks in the USA has increased from 33 to 44 per 100,000 adults, and at present AP accounts for more than 200,000 hospital admissions per year. AP is a relatively common disease in Europe, with a case incidence of 10 to 30 per 100,000 inhabitants. In 80% of the cases, the disease is mild, without significant morbidity or mortality. However, in 20% of the patients the disease is severe, with a stable frequency of mortality rate of around 25%-30% (1). The situation giving rise to AP determines its epidemiology. The most frequent cause is biliary stone migration. Alcohol abuse is less frequent in women than in men. In children, the main triggers of AP are trauma, systemic diseases, infections and drugs, whereas genetic causes are rare. Although these etiological agents differ considerably, the ultimate outcome is relatively independent of the causative factors. In the classification systems we can summarise the evolution from Marseille to the Atlanta. The Marseille classification system distinguishes two morphological stages of pancreatitis: an edematous form and an acute necrotizing form, i.e. a pathological classification. From a clinical aspect, the Atlanta classification similarly distinguishes two forms: mild pancreatitis, without any complications, and severe pancreatitis, characterized by systemic and local complications such as necrosis, pseudocysts of the pancreas and multiple distant organ failures.

1.1.1. Diagnosis

Despite the availability of a wide variety of laboratory tests and diagnostic examinations, the diagnosis of AP is mainly based on clinical findings. AP should always be taken into consideration if the patient reports strong continuous pain in the epigastric area or the right

upper quadrant, or sudden tenderness in the abdomen accompanied by nausea and vomiting. The pain may radiate to the back. Exudates forming a necrotic area along the falciform ligament and into the retroperitoneum can be seen in the periumbilical region; this is called Cullen's sign. Routine diagnostic procedures include determinations of the serum amylase and lipase, and the leukocyte count. These enzymes are released from pancreatic acinar cells during AP. The amylase concentrations in the serum generally rise within a few hours after the onset of symptoms, and normalize within 3-5 days. The serum lipase concentration remains elevated for a longer period of time than does the amylase concentration, which is an advantage over amylase measurement in patients with delayed presentation. Assays of many other pancreatic enzymes have been assessed during the past two decades, but none seems to offer better diagnostic value than those of amylase and lipase. Morphologic procedures mainly involve conventional and endoscopic sonography and contrast-enhanced computer tomography (CT). Abdominal radiography may reveal a localized ileus in severe AP with a sentinel loop. In more than one-third of the patients, the chest X-ray demonstrates abnormalities such as the elevation of one hemidiaphragm, and pleural effusions, pulmonary infiltrates or both. Contrast-enhanced CT is essential for the diagnosis, with a sensitivity of 87-90% and a specificity of 90-92%. Magnetic resonance imaging identifies necrosis and fluid collections better than does the CT scan. The most widely accepted score system, the Balthazar score, attempts to take into account the radiological findings and the presence of pancreatic necrosis. The course of AP is generally not predictable. The severity in the initial phase is generally accompanied by the presence of pancreatic necrosis. The extent of organ failure does not always correlate with the extent of pancreatic necrosis (2).

1.1.2. Prognosis

At present, there is no prognostic system which can predict the severity of AP with 100% sensitivity. However, a number of scoring systems and prognostic factors have been proposed for determination of the severity of pancreatic injury, e.g. the Ranson criteria, the acute physiology and chronic health evaluation (APACHE II-III), the sequential organ failure assessment (SOFA) score, the logistic organ dysfunction (LOD) score and the multiple organ dysfunction (MOF) score(3). These scores assess the damage in the extrapancreatic organs; the greater the number of organs injured, the higher the score. These scores should be repeated during hospitalization, because their modification can predict the outcome. The early identification of patients at risk is important for the initiation of intensive therapy, the early detection of complications, and timely intervention (4). The APACHE II and III scores utilize

the physiology, age and chronic health factors to calculate the prognosis. They differ in the total score, the number of physiological variables (12 for APACHE II vs 17 for APACHE III), and the assessment of the chronic health status. It has been proved that the Ranson score furnishes the highest sensitivity and the lowest false-negative rate, with the disadvantage of a 24-h delay. The positive and negative predictive values are of similar extent for all three scores (Ranson, APACHE II and APACHE III). Various types of biochemical markers have been used as tests to predict the clinical outcome, such as the C-reactive protein (CRP), phospholipase A2, antiproteases and procalcitonin. CRP reaches its peak value at later stages in the course of the disease, whereas the levels of proinflammatory cytokines such as interleukin-6 (IL-6) peak much earlier. The levels of most cytokines are significantly higher in necrotizing AP than in the edematous form. Other prognostic markers, such as the serum concentrations of trypsinogen activation peptide, anionic trypsinogen and procalcitonin, may also be of value to estimate the severity of AP (5). However, markers other than CRP are generally not used in routine clinical practice.

1.1.3. Therapy

Unfortunately, the best possible combination of clinical and laboratory parameters for prediction has not yet been determined. As the complications in AP may arise in both the early and the later phases, there may not be a single marker for the entire course of the disease. In the past few years, the availability of several new therapeutic options has changed the management of AP. For the obstructive form of AP there is a clear therapeutic strategy (endoscopic retrograde cholangiopancreatography with sphincterotomy), whereas in the nonobstructive forms of AP, no specific therapy based on the pathophysiological processes involved is available to date. The gold standard includes the early identification of severe AP, aggressive fluid resuscitation to correct fluid losses in the third space and to maintain an adequate intravascular volume, and close monitoring of the respiratory, cardiovascular and renal functions to assess and treat complications associated with hypovolemia. Oral feeding is replaced by parenteral nutrition, and pain relievers, oxygen and antiemetics administration can be helpful. An important aspect as concerns the treatment of AP is the prevention of the infection of the pancreatic necrosis. Enteral feeding plays a pivotal role in this process (6). Various studies have concluded that the systemic inflammatory response syndrome, sepsis, multiple organ failure and intensive care unit stay are globally improved in enterally-fed patients. The acute phase response and the different disease severity scores (APACHE II and CRP) were significantly improved following enteral nutrition without any change in the CT

scan scores. The final conclusion was that this therapy modulates the inflammatory and sepsis response in AP. However, there is no doubt that it is better to administer enteral feeding via a gastric tube rather than via a nasojejunal tube (7). It has not yet been ascertained whether probiotics associated with enteral feeding may become an alternative mode of therapy, replacing early antibiotic use to prevent infection in AP. Infection of pancreatic necrosis is a very important issue, because such infection is the leading cause of morbidity and mortality, the complication developing during the second or third week. When infection is suspected and fine needle-aspiration of the pancreas for bacteriological culture has been performed, the standard treatment is to start antibiotics intravenously. Patients who develop pancreatic necrosis might need debridement and percutaneous or endoscopic drainage of fluid collections, pseudocysts and abscesses (8). However, such interventions are needed only when the pancreatic or peripancreatic tissues are infected. When necrosis is sterile, mortality is low and necrosis is treated by a conservative approach, although surgery might be needed for late complications or persistent severe AP. The conservative strategies focus on interfering with the local release of proinflammatory mediators or modulating the function of the immunocytes. It is important that the clinical outcome is critically dependent on the accurate assessment and treatment of systemic complications.

1.2. Scientific background

During the past twenty years, much evidence has accumulated which indicates that proinflammatory mediators such as tumor necrosis factor- α (TNF- α), certain interleukins (IL-1 beta, IL-6, IL-8 and IL-10) (9-11), prostaglandins, the arachidonic acid metabolism and many other biological active mediators (12, 13) play significant roles in the pathogenesis of AP, which can range from a mild illness to a lifethreatening condition. These mediators are primarily responsible for the distant organ complications (multiorgan failure) in severe AP (14).

The beneficial effect of glucocorticoid hormones in the treatment of human AP was originally reported by Stephenson *et al.* (15) in the early 1950s. Since that time, the role of glucocorticoids has been investigated in various types of *in vivo* and *in vitro* experimental AP models. It has been reported to result paradoxically in the release of both anti-inflammatory (glucocorticoid hormones) and proinflammatory (macrophage migration inhibitory factor; MIF) mediators. This counter-regulatory mechanism is essential for the provision of appropriate control of the ensuing inflammatory cascade.

The glucocorticoids are known to be involved in the regulation of cytokine production and the inflammatory processes. The corticosteroids inhibit the synthesis of TNF- α (16), IL-1, IL-6 and IL-8 and the function of nitric oxide synthase (17, 18), and reduce complement activation and complement-induced leukocyte activation (19).

The proinflammatory cytokines activate the hypothalamic-pituitary-adrenal axis, stimulating pituitary adrenocorticotropin secretion and the resulting release of endogenous glucocorticoids (20), which are the most important endogenous modulators of inflammatory and immune responses (21,22). Recent studies have demonstrated the bidirectional communication between the neuroendocrine and immune systems, and this special feedback loop balances the intensity of the immune response and moderates the morbidity and mortality associated with the systemic inflammatory reaction (23).

Furthermore, glucocorticoids protect the acinar cells (24), stabilize the cell membrane and directly regulate amylase synthesis (25). Nevertheless, the effects of glucocorticoids on the clinical or experimental forms of AP have remained contradictory (26-28).

Low doses of glucocorticoids induce the secretion of MIF (29), a potent proinflammatory molecule which controls the synthesis of glucocorticoids and the action of inflammatory mediators (IL-1, IL-6, IL-8 and TNF) (30). However, this regulatory role of MIF on the anti-inflammatory/immunosuppressive effects of glucocorticoid hormones has not been fully elucidated.

1.3. Aims

Our primary goal was to create clinically relevant animal models suitable for investigations of the pathophysiology of AP and different treatment options

We hoped to gain insight into the action of glucocorticoids in the early phase of experimental AP. We therefore set out to study the consequences of the administration of the exogenous glucocorticoid agonists dexamethasone (DEX), hydrocortisone (HYD) and methylprednisolone (MP) and the antagonist RU-38486 (RU) on the local and systemic responses of AP, including the mortality, the severity, the levels of proinflammatory and inflammatory mediators, the local histopathological changes, and liver and lung injuries in experimental AP.

Within this topic we investigated,

- the effects of glucocorticoid agonist and antagonist hormones on the mortality in AP;
- the effects of glucocorticoid agonist and antagonist hormones on the proinflammatory and inflammatory mediators in the plasma and in different target organs in AP;

- the effects of glucocorticoid agonist and antagonist hormones on the changes in pancreatitis markers in AP;
- the characterization of leukocyte infiltration by myeloperoxidase (MPO) in distant target organs the liver and lungs in AP;
- the role of adenosine triphosphate (ATP) level changes in distant target organs the liver and lungs in AP;
- the effects of glucocorticoid agonist and antagonist hormones on MIF level regulation;
- the role of glucocorticoid hormones in the regulation of the pancreatic nuclear transcription factor kappa B (NF- κ B) activity;
- the effects of glucocorticoids on histological changes in the pancreas and distant organs the lungs and liver in experimental AP models.

2. MATERIALS AND METHODS

The experiments were performed in adherence to the National institutes of Health guidelines for the use of experimental animals. The study was approved by the Ethical Committee of the University of Szeged for the Protection of Animals in Scientific Research.

Animals

Male outbred Wistar rats (weighing 250-280 g) from the breeding facilities of the University of Szeged were maintained on standard laboratory diet and tap water *ad libitum*; they were fasted for 12 h before the induction of AP. The animal room was maintained on a 12-h light/12-h dark diurnal cycle at a constant temperature of 22 °C. All animals were allowed to acclimatize for 1 week.

2.1. Experimental protocols

2.1.1. Study I

The animals were allocated to one or other of eight groups. In group 1, AP was induced by the retrograde administration of 400 mg Na-taurocholate into the pancreatic duct (group AP). In groups 2, 3 and 4, the animals were given 4 mg/kg body weight (bw) dexamethasone (DEX)

(Oradexon, Organon) (group APD), or 20 mg/kg bw hydrocortisone (HYD) (Solu-Cortef, Pharmacia&Upjohn) (group APH) or 5 mg/kg bw RU (Roussel-Uclaf, France) (group APRU) subcutaneously just prior to the induction of AP. RU was incorporated into multilamellar phospholipid liposomes prepared from phosphatidylcholine (Sigma Chem., U.S.A.) and cholesterol (Sigma Chem., U.S.A.) according to the method described earlier (31). In sham-operated groups 5-8, the animals underwent the same surgical interventions, but sterile saline was used as infusate into the pancreas (group Sham) or the animals received subcutaneously (sc.) the same doses of DEX (group ShamDEX), HYD (group ShamHYD), or RU (group ShamRU).

The animals were randomly assigned into one or other of three experimental series. In series 1 (n = 48), the mortality of AP was investigated. The animals were observed for 24 h, and the number of survivors was recorded. Series 2 (n = 178) was used for serum cytokine, amylase and pancreatic weight/body weight (pw/bw) determinations. Blood samples were obtained 2, 4, 8 and 24 h after AP induction. Tissue biopsies were taken for ATP and MPO measurements of the liver and lungs, and for histology of the pancreas, 24 h after AP induction. In the sham-operated series 3 (n = 60) blood samples were taken at 4 and 8 h, and tissue biopsies were taken at 24 h after surgery.

2.1.2. Study II

In the second study, the rats were randomly allocated into one or other of three groups. In the group AP, AP was induced by the intraperitoneal (ip.) administration of L-arginine (L-Arg) (2 x 250 mg/100 g bw). In groups APMP and APRU, the animals were given 30 mg/kg MP, (Organon) or 5 mg/kg RU (Roussel-Uclaf, France), respectively. The agonist and antagonist were administered sc. just prior to the induction of AP. In the control group (group C), the animals were given a saline injection sc. and were euthanized at 0, 8, 12 or 24 h without undergoing any other procedure. Each group contained at least 6 animals.

2.2. Surgical preparation

2.2.1. Experimental acute pancreatitis

In the first study, the surgical procedures were performed under Na-pentobarbital (40 mg/kg ip) anesthesia. The abdomen was shaved, prepped, and draped in sterile fashion, and after a midline laparotomy, the pancreatic duct was cannulated at its entry into the duodenum, using a PE 50 catheter, fixed and connected to a pressure-controlled precision pump (IVAC, San Diego, CA). Prior to infusion, the common bile duct was occluded with a microvascular metal

aneurysm clamp at the hilus of the liver, where the infusate entered the pancreas. 400 µl 3% Na-taurocholate (Sigma, U.S.A.) was perfused under standard parameters (pressure and volume) for 30 s. After the intraductal infusion, the bile duct clamp was removed, the cannula was withdrawn, and the abdomen was closed in two layers.

In the second series, the experimental AP was induced by the ip. administration of L-Arg (2x250 mg/100 g bw).

2.2.2. Collection and analysis of plasma samples

Rats were laparotomized and sacrificed by abdominal aorta exsanguination under pentobarbital anesthesia 2, 4, 8, or 24 h in study I or 0, 8, 12 and 24 h following AP induction in study II. Blood samples were collected in heparinized tubes by exsanguinating the animals through the abdominal aorta. The blood was centrifuged at 3000 g for 10 min immediately after collection, and the plasma was separated through the use of sterile pipets and stored at -70 °C until it was assayed.

2.3. Measurements

2.3.1. Survival analysis

In the first experiments, we investigated the survival rates 24 h after the induction of experimental AP by taurocholic acid. In the second series, survival analysis was not performed because in this dose the L-Arg-induced AP did not result in mortality.

2.3.2. Pancreatic weight / body weight (pw/bw) ratio determination

The pancreas was removed immediately after the blood collection, trimmed free of fat and lymph nodes, and weighed. The pw/bw ratio (mg/g) was calculated for each animal, to estimate the level of pancreatic edema.

2.3.3. Plasma amylase activity

Plasma amylase levels were measured by the amylase test of Phadebas *et al.* (32) and are reported in standard units.

2.3.4. Cytokine assays

2.3.4.1. Plasma IL-6 activity

IL-6 was bioassayed by using the murine hybridoma cell line B9, the proliferation of which is IL-6-dependent (33). The proliferation of hybridoma cells stimulated with plasma was

determined by the colorimetric MTT assay (involving the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) after incubation for 72 h. All samples were assayed in duplicate.

2.3.4.2. Macrophage migration inhibitory factor activity

Plasma MIF concentration was measured with a sandwich enzyme immunoassay kit (Chem. Int. Inc., USA) according to the manufacturer's instructions.

2.3.5. Assay of inflammatory mediator in pancreatic tissue

Nuclear transcription factor kappa B analysis

The proinflammatory cytokines TNF and IL-1-beta are known to activate NF- κ B. This fact was made use of to estimate the production of inflammatory mediators in tissue homogenates (where the reliability of other assays is limited).

Tissue biopsies were taken at 0, 8, 12 and 24 h following AP induction, trimmed free of fat and lymph nodes, weighed and frozen at -70 °C until use. After mincing and ultrasonic homogenization, the debris was pelleted by low-speed centrifugation and the supernatant was used for the assay.

2.3.6. Reporter cell lines

Mouse L929 cells (5×10^5 cells on a 60-mm plate) were transformed with pNF- κ B-luc4 and pSV-2/neo plasmids (coding for firefly luciferase under the control of 5 NF- κ B-responsive elements and the *neo^r* gene controlled by the SV40 enhancer/promoter, respectively), using the DMIRIE-C cationic lipid transfection agent (GIBCO BRL). Selection on Geneticin G418 (400 mg/l) started 48 h later, the medium being refreshed twice weekly. Clones were isolated and tested for the intensity of their TNF-elicited NF- κ B induction (50-100 U/ml recombinant TNF, 6-10 h of induction) and the most responsive clones were used in subsequent experiments.

RAW 264.7 cells (5×10^5 /60-mm plate) subcultured on the previous day were transformed overnight with the above plasmids complexed with polyethylene-imine (jetPEI, Qbiogen, Illkirch, France). Geneticin-containing medium (400 mg/l) was replaced daily from day 2; clones were isolated after 12 days. The clones exhibiting the highest response to lipopolysaccharide (LPS) activation (0.1 to 10 μ g/ml, 6-10 h of incubation) were used for the assays.

2.3.6.1. Media

Both cell types were grown in MIX MEM (a 1:1 mixture of DMEM, Sigma Cat. no. D-7777 and F-12 HAM, Sigma Cat. No. N-4388) plus 10% fetal calf serum (FCS) (Sigma, Cat. no. F-4135). Transformation was carried out in OPTI MEM (GIBCO BRL). Geneticin was purchased from Sigma (Cat. no. A-1720).

2.3.6.2. Luciferase assay

One-day-old cultures (of both L929 and RAW 264.7 cells), grown on luminoplates (Corning-Costar Cat. no 3903) at 3×10^4 cells/well in MIX MEM 10% FCS, were exposed to tissue samples, TNF or LPS, respectively (in 100 μ l of the above medium per well).

After 6 h of incubation, the medium was removed and the cells were washed and lysed for 10 min at room temperature in buffer (20 μ l/well, Promega Cat. no. E 1531). Substrate was added (20 μ l/well, Promega Cat. no. E 2620) and the luciferase activity was measured in a Luminoskan Ascent (Thermo Labsystems) scanning luminometer.

2.3.7. Analysis of liver and lung tissue samples

Simultaneously with the pancreas-removing processes, tissue samples were obtained from the liver and lungs and immediately processed, snap-frozen in liquid nitrogen for MPO and ATP assays, and stored at -37°C .

2.3.7.1. Myeloperoxidase activity

The tissue MPO activity, as a marker of tissue leukocyte infiltration, was measured in liver and lung biopsies by the method of Kuebler *et al.* (34). Briefly, the tissue was homogenized with Tris-HCl buffer (0.1 M, pH 7.4) containing 0.1 mM polymethylsulfonyl fluoride to block tissue proteases, and then centrifuged at 4°C for 20 min at 2000 g. The MPO activities of the samples were measured at 450 nm (UV-1601 spectrophotometer, Shimadzu, Japan), and the data were referred to the protein content.

2.3.7.2. ATP measurement

Samples were taken from the liver and lungs with a Wollenberg forceps cooled in liquid nitrogen, and the tissue was stored at -70°C . The samples were weighed, placed into a 3-fold volume of trichloroacetic acid (6% w/v), homogenized for 1 min, and centrifuged at 5000 g. The supernatant was neutralized with saturated potassium carbonate solution. The ATP

concentration was measured spectrophotometrically according to Lamprecht *et al.* (35). The method is based on the principle that beta-nicotinamide adenine dinucleotide phosphate is consumed in an enzymatic reaction catalyzed by glucose-6-phosphate dehydrogenase and hexokinase.

2.3.8. Histology

Tissue biopsies were taken for histology of the pancreas, lungs and liver 24 h after AP induction. The severity of the AP was determined by gross scoring of the macroscopic parameters of the pancreas pathology, including pancreatic edema, hemorrhage and fat necrosis. The gross pathologic scoring of the pancreas was performed according to the following criteria: I. pancreatic edema: 0 = absent, 1 = mild gland swelling, no cysts, 2 = moderate gland swelling, cysts in the duodenal region, 3 = severe gland swelling, multiple cysts extending to the splenic region; II. pancreatic fat necrosis: 0 = absent, 1 = confined to the pancreas, 2 = extending to the omentum, 3 = widespread to the retroperitoneum; III. pancreatic hemorrhage: 0 = absent, 1 = punctate, periductal, 2 = diffuse within the pancreas, 3 = peripancreatic or pancreatic blood with clots.

The pancreatic histology was scored by the method of Hughes *et al.* (36) with minor modifications: edema: 0 = absent; 0.5 = focal < 50%; 1.0 = diffuse > 50%; vascular change: 0 = absent; 0.5 = congestion; 1.0 = focal hemorrhage; 1.5 = diffuse hemorrhage; 2.0 = vascular necrosis or thrombosis; inflammation: 0 = absent; 0.5 = focal/mild; 1.0 = diffuse; acinar necrosis: 0 = absent; 0.5 = single acinar cell necrosis/foci of peripheral lobular damage; 1.0 = lobular necrosis; 1.5 = lobular necrosis with microabscesses; fat necrosis: 0 = absent; 0.5 = present.

The systemic damage involved in the pancreatitis was scored for 24 h in different target organs such as the liver and lungs. Histologic scoring of the liver (hepatic damage index) was performed with the following criteria: portal region: inflammation (0 - 3+), bile duct proliferation (0 - 3+), fibrosis (0 - 3+); periportal region: piecemeal necrosis (0 - 3+), acute cholangiohepatitis (0 - 3+), bridging fibrosis (0 - 3+); intralobular alteration: cholestasis (0 - 3+), focal necrosis (0 - 3+), multiacinar necrosis (0 - 3+), Kupffer cell hyperplasia (0 - 3+), regeneration (0 - 3+), and steatosis/degeneration (0 - 3+).

Histologic scoring of the lungs (pulmonary damage index) was performed according to the following criteria: bronchial lesion (grade: 0 - 3+), alveolar lesion (grade: 0 - 3+), vascular changes (grade: 0 - 3+), and interstitial changes (grade: 0 - 3+).

2.3.9. Light microscopy

2-3-mm³ portions of the same segment of the organs (pancreas, liver or lungs) were fixed in 10% neutral formaldehyde solution after weighing (only in the case of the pancreas) and subsequently embedded in paraffin wax. Deparaffinized 4- μ m-thick sections were stained with hematoxylin and eosin. The slides were coded and read for the histological markers of tissue injury by one independent observer in a blinded fashion. The different special histological signs were graded semiquantitatively in 8-10 consecutive high-power fields (x400). The score for each graded parameter was averaged and the total tissue damage was calculated by summing the averages.

2.3.10. Data analysis and statistical comparisons

Data analysis was performed with the Sigmastat for Windows statistical software package (Jandel Scientific, Erkrath, Germany). Survival data were analyzed for statistical significance by the Fisher exact test. In the case of biochemical measurements for statistical analysis, a nonparametric method was used. Time-dependent differences from the baseline were assessed by Dunn's method. Differences between groups were analyzed with Kruskal-Wallis one-way analysis of variance on ranks, followed by Dunn's method for pairwise multiple comparison. *P* values <0.05 were considered statistically significant. Results are expressed as means \pm S.E.M.

3. RESULTS

3.1. Study I

3.1.1. Survival analysis

In the non-treated AP group, the experimentally induced AP resulted in a 33% (4/12) survival rate, with a median survival of 10 h after an observation period of 24 h. However, the glucocorticoid agonists decreased the lethal effect of AP: in the groups APD and APH, the 24-h survival rates were 58% (7/12) and 75% (9/12), with a median survival of 17 and 19 h, respectively. In the group APRU, the resistance of the animals against AP was significantly decreased as compared with the groups APD and APH: the survival rate was only 17% (2/12). In the Sham group, the mortality was 0 (Fig. 1).




Figure 1.

Survival analysis for 24 h in Na-taurocholate-induced AP in rats. Abbreviations: SHAM: sham-operated animals, AP: acute pancreatitis, APRU: RU-38486-treated animals, APD: dexamethasone-treated animals, APH: hydrocortisone-treated animals. Data are means \pm S.E.M. * $p < 0.05$ vs the groups APD and APH.

3.1.2. Pancreatic weight / body weight ratio

Pw/bw was significantly elevated in the group AP vs the normal condition ($p < 0.05$). No difference between the groups AP and APRU was found at any time point. In the groups APD and APH, pw/bw was significantly diminished ($p < 0.05$) vs the group AP (Fig. 2). In the SHAM groups, the pw/bw ratio did not change significantly.




Figure 2.

Changes in pw/bw ratio in Na-taurocholate-induced AP in rats. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APD: dexamethasone-treated animals, APH: hydrocortisone-treated animals. All values are averages of at least 7 determinations. Data are means \pm S.E.M. * $p < 0.05$ vs basal pw/bw ratio, # $p < 0.05$ vs the group AP.

3.1.3. Plasma amylase activity

In the group AP, the amylase activity was significantly elevated at 2 h (13000 U/l \pm 3000 U/l) and remained higher at 4, 8 and 24 h vs the basal level ($p < 0.05$). In the glucocorticoid agonist-treated groups (groups APD and APH), the plasma amylase levels were significantly decreased as compared with the group AP at 2, 4 and 8 h ($p < 0.05$). No significant alteration in amylase activity was found in the group APRU vs the group AP (Fig. 3). In the SHAM group, the glucocorticoid agonists and antagonists did not alter the basal amylase level significantly at any time point as compared with saline treatment.




Figure 3.

Effects of glucocorticoid agonists (DEX and HYD) and glucocorticoid antagonist (RU) on the amylase activity in Na-taurocholate-induced AP. Plasma amylase activity was measured 0, 2, 4, 8 and 24 h after AP induction. All values are averages of at least 7 determinations. Data are means \pm S.E.M. * $p < 0.05$ vs basal amylase level. # $p < 0.05$ vs the group AP. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APD: dexamethasone-treated animals, APH: hydrocortisone-treated animals.

3.1.4. Plasma IL-6 activity

In the group AP, the IL-6 level gradually increased, reaching its peak at 8 h ($13500 \text{ U/l} \pm 3000 \text{ U/l}$). In the group APRU, the IL-6 value was significantly elevated ($16000 \text{ U/l} \pm 3800 \text{ U/l}$) at 2h following AP induction as compared with the other groups ($p < 0.05$). At 4, 8 and 24 h, its levels did not differ from those for the group AP. In the groups APD and APH, the IL-6 activity was significantly diminished ($p < 0.05$) as compared with the group AP at 4, 8 and 24 h (Fig. 4). The circulating IL-6 level did not change significantly in the SHAM group.




Figure 4.

Changes in plasma IL-6 level in Na-taurocholate-induced AP in rats. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APD: dexamethasone-treated animals, APH: hydrocortisone-treated animals. All values are averages of at least 7 determinations. Data are means \pm S.E.M. * $p < 0.05$ vs basal plasma level of IL-6. # $p < 0.05$ vs the group AP.

3.1.5. Liver and lung MPO activity

AP significantly elevated the leukocyte accumulation both in the liver and in the lungs ($p < 0.05$) as compared with the SHAM group (Figs. 5 and 6). RU treatment did not influence the MPO activities of the organs as compared with the group AP. DEX and HYD, however, significantly ($p < 0.05$) attenuated the leukocyte accumulation in the liver 24 h following AP induction as compared with the AP group. In the glucocorticoid agonist and antagonist-treated SHAM groups, the MPO activity did not change significantly as compared with saline treatment.




Figure 5.

Liver MPO values in Na-taurocholate-induced AP in rats. Abbreviations: AP: acute pancreatitis, APRU: RU-38486 treated animals, APD: dexamethasone-treated animals, APH: hydrocortisone-treated animals, Sham: sham-operated, saline-treated animals. All values are averages of at least 7 determinations. Data are means \pm S.E.M. ^x $p < 0.05$ vs the group Sham. [#] $p < 0.05$ vs the group AP.




Figure 6.

Lung MPO values in Na-taurocholate-induced AP in rats. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APD: dexamethasone-treated animals, APH: hydrocortisone-treated animals, SHAM: sham-operated, saline-treated animals. All values are averages of at least 7 determinations. Data are means \pm S.E.M. ^x $p < 0.05$ vs the group Sham.

3.1.6. Liver and lung ATP activity

AP alone resulted in significantly decreased ATP levels in both the liver and the lung tissue at the end of the observation period as compared with the Sham group ($p < 0.05$). In the group APRU, the liver and lung ATP levels were similarly significantly ($p < 0.05$) decreased vs the group Sham, but did not differ from that for the group AP. In the groups, APD and APH, the liver ATP levels were significantly ($p < 0.05$) elevated as compared with the group AP (Fig. 7).

No significant differences were detected between the groups AP and APRU vs the groups APD and APH in the lung tissue ATP level. In the Sham groups (Sham, ShamDEX, ShamHYD and ShamRU), the ATP contents of the liver and lung tissue did not change significantly as compared with saline treatment.




Figure 7.

Changes in liver ATP level 24 h following AP induction. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APD: dexamethasone-treated animals, APH: hydrocortisone-treated animals, Sham: sham-operated, saline-treated animals. All values are averages of at least of 7 determinations. Data are means \pm S.E.M. ^xp<0.05 vs the group Sham. [#]p<0.05 vs the group AP.

3.1.7. Gross pathology

The results of the gross pathology scoring are shown in Table I. The scores were significantly improved in the groups APH and APD as compared with the group AP ($p<0.05$). In the AP and the groups APRU, macroscopic analysis revealed more severe pathological parameters than in the groups APH and APD.

Table I.

Gross pathologic scoring results in AP

Tested parameters	AP	APRU	APH	APD
Pancreatic edema	2.2 ± 0.7	3.0 ± 0.0	1.22 ± 0.7*	1.4 ± 0.5
Pancreatic hemorrhage	1.7 ± 0.2	2.5 ± 0.5	1.33 ± 0.6	1.4 ± 0.5
Pancreatic fat necrosis	2.2 ± 0.7	3.0 ± 0.0	1.0 ± 0.0*	1.1 ± 0.8*

* p<0.05 vs the group AP

3.1.8. Histology

Although the gross pathological and the microscopic findings following hematoxylin-eosin staining demonstrated appreciable histological changes in the pancreas, liver and lungs in the different groups, the differences in the investigated organs were not statistically significant.

3.2. Study II

3.2.1. Pancreatic weight / body weight ratio

The administration of L-Arg significantly increased the pw/bw ratio vs that in the group Control (p<0.05). Glucocorticoid pretreatment tended to decrease the pw/bw ratio in the AP group, but this difference was not statistically significant (Fig. 7).




Figure 7.

Changes in pancreatic weight to body weight ratio (pw/bw) in L-Arg-induced AP in rats. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APMP: methylprednisolone-treated animals. All values are averages of at least 6 determinations. Data are means \pm S.E.M. * $p < 0.05$ vs basal pw/bw ratio.

3.2.2. Plasma amylase activity

In the AP and APRU groups, the amylase activities were significantly elevated at 12 h and remained higher at 24 h vs the basal level ($p < 0.05$). In the glucocorticoid agonist-treated group (group APMP), the plasma amylase level was significantly decreased as compared with the groups AP and APRU at 12 and 24 h ($p < 0.05$). No significant alteration in amylase activity was found in the group APRU vs the group AP (Fig. 8).




Figure 8.

Effects of glucocorticoid agonist (MP) and glucocorticoid antagonist (RU) on amylase activity in L-Arg-induced AP. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APMP: methylprednisolone-treated animals. All values are averages of at least 6 determinations. Data are means \pm S.E.M. * $p < 0.05$ vs basal amylase level. # $p < 0.05$ vs the group AP.

3.2.3. Plasma IL-6 activity

In the group AP, the IL-6 level gradually increased, reaching its peak (1000 ± 200 U/l) at 8 h. In the group APRU, the IL-6 level was significantly elevated (750 ± 100 U/l) at 8 h and 12 h following AP induction as compared with the group APMP ($p < 0.05$). In the group APMP, the IL-6 activity was significantly diminished ($p < 0.05$) as compared with the group AP at 8 h. The circulating IL-6 level did not differ significantly between the groups AP and APMP from 12 h up to the end of the observation period (Fig. 9).




Figure 9.

Changes in plasma IL-6 level in L-Arg-induced AP in rats. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APMP: methylprednisolone-treated animals. All values are averages of at least 6 determinations. Data are means \pm S.E.M. * $p < 0.05$ vs basal plasma level of IL-6. # $p < 0.05$ vs the group AP. $^x p < 0.05$ the group APRU vs the group APMP.

3.2.4. Plasma MIF level

AP induced increases in the baseline plasma MIF level at 8, 12 and 24 h. MP did not exert a significant effect on the plasma MIF level changes. RU treatment resulted in significantly higher MIF production at 8 and 12 h following L-Arg injection as compared with the groups APMP and AP (Fig. 10).




Figure 10.

MIF values in L-Arg-induced AP in rats. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APMP: methylprednisolone-treated animals, Control: saline-treated animals. All values are averages of at least 6 determinations. Data are means \pm S.E.M.

* $p < 0.05$ vs the basal MIF level. # $p < 0.05$ vs the group AP. ^x $p < 0.05$ the group APRU vs the group APMP.

3.2.5. Proinflammatory cytokines in the pancreas

In the early phase of AP, the level of pancreatic NF- κ B activity changed in parallel in the MP- and RU-treated groups, and the difference between these groups was not statistically significant at 8 h following L-Arg injection.

MP treatment significantly decreased the level of NF- κ B activity as compared with the RU-treated animals at 12 h following AP induction. Similarly, in the group APMP the pancreatic NF- κ B concentration was significantly decreased as compared with the group AP at 24 h. RU treatment resulted in a significantly higher level of pancreatic NF- κ B activity at 12 h vs the groups AP and APMP. AP alone led to a significantly higher NF- κ B activity as compared with the group C at 24 h (Fig. 11).




Figure 11.

Pancreatic NF- κ B activity in L-Arg-induced AP in rats. Abbreviations: AP: acute pancreatitis, APRU: RU-38486-treated animals, APMP: methylprednisolone-treated animals, Control: saline-treated animals. All values are averages of at least 6 determinations. Data are means \pm S.E.M. * $p < 0.05$ vs the basal level. # $p < 0.05$ vs the group AP. $^x p < 0.05$ the group APRU vs the group APMP.

3.2.6. Gross pathology

The administration of 2x250 mg/100 g bw L-Arg induced mild necrotizing AP. The results of the gross pathology scoring are presented in Table II.

Table II.Gross pathologic scoring results of the pancreas 24 h after induction of AP.

Tested parameters	AP	APRU	APMP
Pancreatic edema	2.1 ± 0.4	3.1 ± 0.0	1.2 ± 0.7*
Pancreatic hemorrhage	1.6 ± 0.3	2.4 ± 0.4	1.3 ± 0.6
Pancreatic fat necrosis	2.0 ± 0.6	2.9 ± 0.2	1.1 ± 0.0*

*p<0.05 vs the group AP

The scores were significantly better in the group APMP as compared with the group AP (p<0.05). In the group APRU, the macroscopic analysis revealed more severe pathological parameters than in the group APMP.

3.2.7. Histology

On hematoxylin-eosin staining, the microscopic investigations demonstrated major histological changes in the pancreas, liver and lungs in the different groups (Tables III-V).

Table III.Histological scoring results on the pancreas 24 h after induction of AP.

Tested parameters	AP	APRU	APMP
Pancreatic edema	0.6 ± 0.0	0.7 ± 0.0	0.3 ± 0.0* [#]
Vascular change	0.9 ± 0.2	1.1 ± 0.1	0.8 ± 0.2
Inflammation	0.7 ± 0.1	0.7 ± 0.2	0.5 ± 0.0* [#]
Acinar necrosis	1.1 ± 0.2	1.2 ± 0.3	0.8 ± 0.2* [#]
Fat necrosis	0.3 ± 0.0	0.4 ± 0.1	0.3 ± 0.0

*p<0.05 vs the group AP

[#]p<0.05 vs the group APRU

Table IV.Histological scoring results on the liver 24 h after induction of AP.

Tested parameters	AP	APRU	APMP
<u>I. Portal region</u>			
Inflammation	1.3 ± 0.1	1.7 ± 0.1	1.3 ± 0.2 [#]
Bile duct proliferation	1.1 ± 0.1	1.0 ± 0.2	1.0 ± 0.1
Fibrosis	0.7 ± 0.1	0.9 ± 0.2	0.6 ± 0.2
<u>II. Periportal region</u>			
Piecemeal necrosis	1.4 ± 0.3	1.5 ± 0.4	1.3 ± 0.2
Acute cholangiohepatitis	1.7 ± 0.4	1.9 ± 0.5	1.6 ± 0.6
Bridging fibrosis	0.7 ± 0.5	0.9 ± 0.3	0.6 ± 0.3
<u>III. Intralobular alteration</u>			
Cholestasis	1.2 ± 0.1	1.5 ± 0.3	1.3 ± 0.3
Focal necrosis	1.3 ± 0.3	1.4 ± 0.2	1.4 ± 0.3
Multiacinar necrosis	1.1 ± 0.1	1.4 ± 0.2	1.0 ± 0.1 [#]
Kupffer cell hyperplasia	1.3 ± 0.3	1.2 ± 0.4	1.1 ± 0.3
Regeneration	0.7 ± 0.2	0.6 ± 0.3	0.7 ± 0.3
Steatosis/degeneration	1.1 ± 0.2	1.1 ± 0.2	1.2 ± 0.3

*p<0.05 vs the group AP

[#]p<0.05 vs the group APRU

Table V.Histological scoring results on the lungs 24 h after induction of AP.

<u>Tested parameters</u>	<u>AP</u>	<u>APRU</u>	<u>APMP</u>
Bronchial lesion	1.2 ± 0.1	1.1 ± 0.3	1.1 ± 0.2
Alveolar lesion	1.2 ± 0.2	1.8 ± 0.3	1.1 ± 0.1 [#]
Vascular changes	1.4 ± 0.2	1.5 ± 0.3	0.9 ± 0.1 ^{*.#}
Interstitial changes	1.7 ± 0.1	2.1 ± 0.2	1.2 ± 0.0 ^{*.#}

*p<0.05 vs the group AP

[#]p<0.05 vs the group APRU

However, at the end of the observation period, the extents of tissue damage in the pancreas and lungs were significantly less in the group APMP than in the groups AP and APRU.

4. DISCUSSION

AP is an inflammatory disorder of the pancreas with local and systemic manifestations, is a significant health problem. In spite of the improvements that have been achieved in intensive care and in surgical therapy, the mortality rate for necrotizing AP remains high. The clinical presentation may range from a local inflammatory process to a severe pancreas injury associated with extrapancreatic manifestations, such as circulatory, renal or pulmonary complications. Activation of the inflammatory cascade, including different cytokines, results in microcirculatory disturbances and multiple organ failure (9). A large body of evidence has revealed that the AP-induced systemic inflammatory response leads to multiple organ dysfunctions, the intensity of this process determining the outcome of the illness (11). In view of its acute onset, rapid progress and high mortality, it has become a hot clinical and experimental study topic and one of the toughest medical problems.

Among the most important aspects of the *in vivo* investigation of AP is the use of a relevant animal model which is able to mimic the clinical situation. Different experimental models of AP have been developed in order to seek an understanding of its pathophysiology, histological features and degree of severity, and the failure of distant organ systems. The interpretation of AP has changed from the early traditional autodigestion theory to the “inflammatory mediator or cytokine theory”, the “microcirculation disturbance theory”, the “nitrogen monoxide and oxygen free radical injury theory”, the “bacteria translocation theory”, and so on. Chan and Leung (37) have surveyed the most relevant animal models of AP and their advantages and limitations. However, there are significant differences in the pathophysiological responses between species and models, and the selection of a particular model depends upon the specific aims of the experiment.

In order to demonstrate the effects of glucocorticoids on AP we chose a severe model of AP. In study I, we applied the Na-taurocholate-induced AP model. This is an accepted and reproducible model of experimental AP, which produces the characteristic morphological and physiological changes of severe necrotizing type AP. To standardize the inflammatory processes and to avoid ductal disruption, we used an infusion pump and constant experimental parameters. The biochemical and morphological data proved that Na-taurocholate administration did result in a severe necrotizing type of AP. In study II, we also chose a severe pancreatitis model. The L-Arg-induced noninvasive model is highly reproducible and standardizable, and produces selective, dose-dependent AP. With a low dose of L-Arg, the induced pancreatitis is not so severe and does not result in mortality. Accordingly, this model

is appropriate for the observation of different pathophysiological changes during experimental pancreatitis of mild severity.

Increases in tissue corticosteroid levels during an acute illness are important protective responses. There is now preliminary evidence to support the use of supplementary corticosteroids in patients with established septic shock, and especially those who display signs of functional hypoadrenalism (38).

However, the beneficial effects of exogenously administered corticosteroid hormones in experimentally induced AP are a matter of dispute. It is well known that the pituitary-adrenal axis, including glucocorticoids, plays a pivotal role in the mutual control mechanisms and communication between the neuro-endocrine and immune systems. During experimental AP, the extent of secretion of endogenous corticosterone is increased (39). Adrenalectomy is known to produce more severe AP and to elevate the serum IL-8 level.

Our results clearly demonstrate that glucocorticoid hormones attenuate the local and systemic effects of AP and prolong the survival of rats.

The injection of HYD during the development of AP was observed by Pescador *et al.* and by De Dios *et al.* to be harmful (26, 40). In contrast, the protective effects of corticosteroids in AP have been reported by several authors (11, 27). Furthermore, glucocorticoids have been found to attenuate the pancreas damage by protecting acinar cells during cerulein-induced AP (24), whereas the opposite was reported by Manso *et al.* (41) in AP induced with a choline-deficient, ethionine-supplemented diet.

Our observations are in line with these findings, since the glucocorticoid agonists HYD, DEX and MP moderated the serum amylase and IL-6 activities and local inflammatory reactions. In contrast, the glucocorticoid antagonist RU amplified the inflammatory processes and resulted in an earlier IL-6 response to AP.

It has been established that the steroid receptor antagonist RU enhances the synthesis of TNF- α and sensitizes animals to the cytotoxic action of TNF- α (42). RU acts at the receptor level, and thus the increased TNF- α production seems to be mediated via the glucocorticoid receptors (43). As the most powerful inducer of IL-6 production is TNF- α , and glucocorticoids inhibit IL-6 synthesis directly (17), the earlier significant IL-6 production in the RU group can be explained.

One of the crucial points of these studies is the timing of steroid treatment during AP (39, 44). Thcolakov *et al.* (45) and Gloor *et al.* (27) observed that treatment with a single prophylactic, low dose of exogenous steroid resulted in a decrease in the severity of AP. Repeated long-term HYD pretreatment has been demonstrated to worsen the inflammatory

process in AP (41). Another controversial point is the dose of steroid treatment. High-dose corticosteroid treatment (30 mg/kg bw) increases the mortality rate, possibly due to secondary infection (28). On the other hand, low-dose (10 mg/kg bw) steroid treatment results in a more effective inhibition of inflammatory mediators (IL-8, TNF- α and arachidonic metabolisms), a better survival and a lower rate of side-effects (46). The opposite was reported by Gloor *et al.* (27): they administered 10 mg/kg bw HYD 10 min following the induction of cerulein-induced AP, but this did not result in any protective effect. These controversial results might be explained by the differences in timing, the dose of glucocorticoid treatment and the type of experimental AP. We used twice as high a dose of HYD (20 mg/kg bw), and a much stronger glucocorticoid analog, DEX, in a dose of 4 mg/kg bw. In spite of the differences in biological half-life, the two steroid analogs achieved the same result. These findings suggest that even the glucocorticoid compound with weaker anti-inflammatory potency (i.e. HYD) could adequately attenuate the inflammatory mediator response in this setting.

Recent studies have led to the rediscovery of a pituitary mediator that appears to act as the counter-regulatory hormone for corticoid action within the immune system. The protein historically known as MIF was identified more than 40 years ago as a product of antigen-sensitized lymphocytes that could inhibit the random movement or migration of cultured mononuclear cells *in vitro* (47, 48).

Low concentrations of glucocorticoids directly induce MIF release from macrophages and T cells (16). This finding was initially surprising because it was generally considered that glucocorticoids inhibit the release of proinflammatory mediators (49, 50). The glucocorticoid-induced secretion of MIF is tightly and dose-dependently regulated (51, 52). At high anti-inflammatory glucocorticoid concentrations ($>10^{-8}$ M), the secretion of MIF is known to be completely shut off (53).

It is of importance that MIF circulates normally in the blood. The basal MIF levels have been estimated by ELISA techniques to range from 2 to 4 ng/ml amounts that demonstrate glucocorticoid counter-regulatory activity *in vitro*. These data suggest that the physiological state of the glucocorticoid-MIF system is one of an active balance between pro- and anti-inflammatory mechanisms (54).

MIF production seems to be upregulated in other cases of pancreatitis too, and its presence can be regarded as an early marker of pancreatic necrosis in AP (55).

We demonstrated that the induction of AP by the injection of L-Arg resulted in a marked increase in the MIF concentration in the plasma. There was a continuous tendency for the administration of high doses of MP to elevate the plasma MIF level, but this effect was not

statistically significant. Our finding had previously been suggested by recent studies on the effects of glucocorticoids on MIF production in different acute inflammatory processes. Nagasaki *et al.* reported that MP did not increase, but rather tended to decrease the serum MIF level (56). Similarly, in experimental rat models Bruhn *et al.* (57) observed that the administration of DEX did not enhance MIF production in sepsis. Our results are in accord with the findings of these authors, who concluded that exogenously administered glucocorticoid treatment downregulated the level of cell-associated MIF and MIF release by various activators (58). The fact that MP did not further increase the production of MIF in our experiments suggested that the degree of glucocorticoid-induced MIF production was already maximal in the AP animals because of the high level of endogenous glucocorticoids. On the other hand, one of the most interesting observations in the second phase of the study was that RU treatment resulted in significant elevations of the plasma level of MIF 8 and 12 h after AP induction. However, there is no clear-cut explanation for this fact. Very little is known about the regulation of the MIF gene; some data suggest that NF- κ B is involved (59, 60).

Glucocorticoid hormones diminish the production of inflammatory cytokines via the inhibition of cytoplasmic transcriptional factors such as NF- κ B (61, 62). The glucocorticoids activate glucocorticoid receptors that may then bind to activated NF- κ B and activator protein-1, preventing binding to κ B sites on genes that have a role in inflammatory processes (63).

Our important major finding is that MIF counteracts the glucocorticoid-mediated inhibition of NF- κ B in L-Arg-induced experimental AP in rats. Our results suggest that NF- κ B activation in L-Arg-induced AP occurs at a later stage as compared with other models. A significant NF- κ B elevation was detected 1 h after the induction of AP with Na-taurocholate (64).

We found that RU treatment led to in significantly higher NF- κ B activity 12 h after pancreatitis induction, which can be explained in that RU treatment results in significantly higher MIF production at this time. It was clear that the short-term pretreatment with a high dose of glucocorticoid caused a significant lowering of the NF- κ B activity in the later phase of AP.

Many inflammatory components are regulated by NF- κ B, including inflammatory cytokines, acute-phase proteins, etc. Glucocorticoid hormones are known to diminish the production of inflammatory cytokines via the inhibition of cytoplasmic transcriptional factors such as NF- κ B (61, 62). Glucocorticoids prevent NF- κ B activation in part by increasing the expression of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (I κ B α), which keeps NF- κ B bound in the cytosol and thereby prevents the gene expression of proinflammatory mediators (63). The mechanism for the counter-regulatory action of MIF

involves the prevention of glucocorticoid-induced increases in cytosolic I κ B α . As a consequence, NF- κ B can translocate to the nucleus and activate transcription, even in the presence of normal physiological concentrations of HYD. MIF could activate an intracellular pathway, leading to I κ B α kinase activation and consequences of I κ B α degradation, in this way overriding the glucocorticoid-induced inhibition of NF- κ B activation (65). Moreover, glucocorticoid increases the expression of I κ B α , preventing NF- κ B translocation to the nucleus and the activation of transcription (49, 50, 65).

We demonstrated that experimental animals respond to AP with a significantly higher degree of tissue leukocyte infiltration, as evidenced by the increased MPO activity in the liver and lungs. It is noteworthy to note that in experimental AP the glucocorticoid agonists attenuated the MPO activity. This finding underlines the importance of the action of glucocorticoid in the control of inflammatory mediator-induced remote organ damage.

Previous nuclear magnetic resonance studies have revealed the depletion of high-energy phosphates in pancreatic cells in AP, which seems to occur as a result of pancreatic cell death (66). Halangk *et al.* (67) reported a correlation between the degree of depletion of high-energy phosphates and the severity of AP. In this process, the main source of the enhanced permeability of the mitochondrial inner membrane is the inhibition of complex I of the respiratory chain. The hepatocellular dysfunction and ATP depletion in AP are also well known (68, 69), but little attention has been paid to the relationship of steroid treatment and the high-energy phosphate level in inflammatory processes of the pancreas. In our study in animals with AP, a significant ATP depletion was demonstrated in remote organs too. The observation that ATP depletion develops in the lungs provides a possible explanation for the pulmonary dysfunction seen in AP. It is also possible that other systemic complications, such as a decreased myocardial contractility or renal failure, are indirectly related to the mitochondrial dysfunction and ATP depletion caused by circulating cytokines and other toxic components. Therefore, our results may suggest a novel explanation for the multiple organ dysfunction and increased morbidity in AP. On the other hand, low-dose steroid treatment was effective in our study, glucocorticoid agonists significantly elevating the liver ATP content in experimental AP.

In our series in the Na-taurocholate-induced AP model, the histological changes in target organs were more characteristic than in the L-Arg-induced series. We proved the protective effect of glucocorticoid analog treatment on tissue damage. Moreover, at the end of the observation period, the extents of tissue damage in the pancreas and lungs were significantly less in the glucocorticoid-treated (APMP) groups than in AP and after Ru treatment.

In conclusion, our study highlights the fact that glucocorticoid hormones play an important role in maintaining the resistance of the animals against the lethal effects of experimentally induced AP. Furthermore, the exogenously administered glucocorticoid agonists greatly moderate the local and systemic inflammatory consequences of experimental AP.

5. SUMMARY AND NEW FINDINGS

The histological and biochemical findings proved that both Na-taurocholate and L-Arg induced a severe type of AP. These two reproducible and standardized *in vivo* experimental models provide useful protocols which furnished valuable information on the functional, morphological and biochemical changes during the initiation phase of AP, and on the pathophysiological and morphological consequences of AP in response to different treatments.

Our results clearly demonstrated that glucocorticoids critically mitigate the progression of the inflammatory reaction during the early phase of experimental AP.

Exogenously administered short-term pretreatment with high-dose glucocorticoid hormones attenuated the local and systemic effects of AP, decreased the serum amylase and IL-6 activities and local inflammatory reaction, and prolonged the survival of the animals.

Our study has proved that experimental animals respond to AP with a significantly higher degree of tissue leukocyte infiltration, as evidenced by the increased MPO activity in the liver and lungs. It must be noted that in experimental AP the glucocorticoid agonists attenuated the MPO activity.

Our study demonstrated a significant ATP depletion in the liver and the lungs of animals with AP. The observation of an ATP depletion in the lungs provides a possible explanation for the pulmonary dysfunction seen in AP. Steroid treatment was effective in our study, glucocorticoid agonists significantly elevating the liver ATP content in experimental AP. Furthermore, inhibition of the endogenous corticosteroid action by RU treatment also resulted in a pronounced ATP depletion in remote organs, this process being inhibited by glucocorticoid agonists.

The induction of AP by the injection of L-Arg led to a marked increase in the MIF concentration in the plasma. There was a continuous tendency for the administration of high doses of MP to enhance the plasma MIF level, but this effect was not statistically significant. On the other hand, treatment with the antiglucocorticoid RU gave rise to significant elevations of the plasma level of MIF after AP induction.

The other important major finding was that MIF counteracted the glucocorticoid-mediated inhibition of NF- κ B in L-Arg-induced experimental AP in rats. Our results suggested that NF- κ B activation in L-Arg-induced AP occurs at a later stage as compared with other models.

We clearly demonstrated that short-term pretreatment with a glucocorticoid agonist resulted in a significant reduction of NF- κ B activity in the later phase of AP.

In conclusion, our study clearly revealed that glucocorticoid agonist treatment promotes the resistance of animals against the lethal effects, and provides considerable protection against the systemic toxicity of inflammatory cytokines of experimentally induced AP.

6. ACKNOWLEDGEMENTS

I would like to express my thanks first and foremost to Professor György Lázár Jr MD, PhD, for initiating my scientific career, for providing me with the opportunity to carry out my scientific work and for his invaluable scientific guidance and help. My studies could hardly have come to fruition without his continuous mental support and advice.

I am very grateful to Professor Tamás Takács MD, PhD, DSc, for inviting to perform experimental work in his laboratory; his helpful comments and constructive criticism were always of enormous help and were greatly appreciated.

I am indebted to Professor György Lázár MD, PhD, DSc, who helped me to master the basic experimental skills and for his valuable scientific discussions.

I wish to thank to Professor Ernő Duda PhD, DSc and Professor Mihály Boros MD, PhD, DSc, for their supports of my research work.

I owe many thanks to Annamaria Szabolcs MD, PhD, my coworker in most of the experimental work.

My thanks are also due to László Tiszlavicz MD, PhD and József Kaszaki MD, PhD, for assisting in the histopathological and cellular evaluations.

I am deeply appreciative of the valuable contributions of Antal Wolfard MD, PhD, to my work.

I wish to express my gratitude to my wife, children and parents for their love, patience and trust.

Last, but not least, all colleagues and staff members at the Institute of Surgical Research, the First Department of Internal Medicine and the Department of Surgery are gratefully thanked for creating such a supportive and pleasant working environment.

This work was supported by grants from the Hungarian Ministry of Health (ETT 57102) and the Hungarian National Research Foundation (OTKA T025402, T042587, T042589, K42587, 5K354, A505 and K60406).

7. REFERENCES

1. Frey CF, Zhou H, Harvey DJ, White RH. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. *Pancreas* 2006; 33: 336-44.
2. Lankisch PG, Pflichthofer D, Lehnick D. No strict correlation between necrosis and organ failure in acute pancreatitis. *Pancreas* 2000; 20:319-22.
3. Triester SL, Kowdley KV. Prognostic factors in acute pancreatitis. *J Clin Gastroenterol* 2002; 34:167-76.
4. Chatzicostas C, Roussomoustakaki M, Vlachonikolis I, *et al.*: Comparison of Ranson, APACHE II and APACHE III scoring systems in acute pancreatitis. *Pancreas* 2002; 25:331-35.
5. Kylanpaa-Back ML, Takala A, Kemppainen E, *et al.*: Procalcitonin strip test in the early detection of severe acute pancreatitis. *Br J Surg* 2001; 88:222-27.
6. Olah A, Belagyi T, Issekutz A, *et al.*: Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. *Br J Surg* 2002; 89:1103-07.
7. Eatock FC, Chong P, Menezes N, *et al.*: A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. *Am J Gastroenterol* 2005; 100:423-39.
8. Werner J, Feuerbach S, Uhl W *et al.*: Management of acute pancreatitis: from surgery to interventional intensive care. *Gut* 2005; 54:426-36.
9. Gloor B, Reber HA. Effects of cytokines and other inflammatory mediators on human acute pancreatitis. *J Intensive Care Med* 1998; 13:305-12.
10. Osman MO, Jensen SL. Acute pancreatitis: The pathophysiological role of cytokines and integrins. *Dig Surg* 1999; 16:347-62.
11. Norman JG. New approaches to acute pancreatitis: Role of inflammatory mediators. *Digestion* 1999; 60:57-60.
12. Heath DI, Cruickshank A, Gudgeon M, *et al.*: Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. *Gut* 1993; 34:41-5.
13. Leser HG, Gross V, Scheibenbogen C, *et al.*: Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. *Gastroenterology* 1991; 101:782-5.

14. Norman JG, Fink GW, Denham W, *et al.*: Tissue-specific cytokine production during experimental acute pancreatitis. A probable mechanism for distant organ dysfunction. *Dig Dis Sci* 1997; 42:1783-88.
15. Stephenson HE Jr., Pfeffer RB, Saypol GM. Acute hemorrhagic pancreatitis. Report of a case with cortisone treatment. *Arch Surg* 1952; 65:307-8.
16. Beutler B, Krochin N, Milsark IW, *et al.*: Control of cachectin (tumor necrosis factor) synthesis: mechanism of endotoxin resistance. *Science* 1986; 232:977-80.
17. Zanker B, Walz G, Wieder KJ, *et al.*: Evidence that glucocorticoids block expression of the human interleukin-6 gene by accessory cells. *Transplantation* 1990; 49:183-5.
18. Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of on inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. *Proc Natl Acad Sci USA* 1990; 87:10043-7.
19. Hammerschmidt DE, White JG, Craddock PR, *et al.*: Corticosteroids inhibit complement-induced granulocyte aggregation: a possible mechanism for their efficacy in shock states. *J Clin Invest* 1979; 63:798-803.
20. Zuckerman SH, Shellhaas J, Butler LD. Differential regulation of lipopolysaccharide-induced interleukin-1 and tumor necrosis factor synthesis: effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. *Eur J Immunol* 1989; 19:301-5.
21. Goldstein RA, Downen DL, Fauci AS. Adrenal corticosteroids. In: *Inflammation: Basic Principles and Clinical Correlates* (Gallin JI, Goldstein IM, Snyderman R) 1992; 2nd Ed:1061-81.
22. Orth DN, Kovacs WJ, DeBold CR. The adrenal cortex. In: *Williams Textbook of Endocrinology* (Wilson JD, Foster DW) 1992; 8th Ed:489-619.
23. Reishi A, Tooru S, Kenji K, *et al.*: The role of endogenous glucocorticoids in rat experimental models of acute pancreatitis. *Gastroenterology* 1995; 109:933-43.
24. Kimura K, Shimosegawa T, Sasano H, *et al.*: Endogenous glucocorticoids decrease the acinar cell sensitivity to apoptosis during cerulein pancreatitis in rats. *Gastroenterology* 1998; 114:372-81.
25. Joachim M, Stephan B, Wolfgang F. Role of glucocorticosteroids in the regulation of pancreatic amylase synthesis. *Pancreas* 1989; 4:194-203.
26. Pescador R, Manso MA, Rebollo AJ, *et al.*: Effect of chronic administration of hydrocortisone on the induction and evolution of acute pancreatitis induced by cerulein. *Pancreas* 1995; 11:165-72.

27. Gloor B, Uhl W, Tcholakov O, *et al.*: Hydrocortisone treatment of early SIRS in acute experimental pancreatitis. *Dig Dis Sci* 2001; 46:2154-61.
28. Bone RC, Fischer CJ, Clemmer TP, *et al.*: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. *N Engl J Med* 1997; 317:653-8.
29. Calandra T, Bernhagen J, Metz CN, *et al.*: MIF as a glucocorticoid-induced counter-regulator of cytokine production. *Nature* 1995; 377:68-71.
30. Bucala R. Neuroimmunomodulation by macrophage migration inhibitory factor (MIF). *Ann New York Acad of Sci* 1998; 840:74-82.
31. Van Rooijen N, Van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. *Cell Tiss Res* 1984; 238:355-8.
32. Ceska M, Birath K, Brown B. A new and rapid method for the clinical determination of amylase activities in human serum and urine. *Clin Chem Acta* 1969; 26:437-44.
33. Aarben LA, De Groot ER, Schaap OL, *et al.*: Production of Hybridoma Growth Factor by human monocytes. *Eur J Immunol* 1987; 17:1411-6.
34. Kuebler WM, Abels C, Schuerer L, *et al.*: Measurement of neutrophil content in brain and lung tissue by a modified myeloperoxidase assays. *Int J Microcirc Clin Exp* 1996; 16:89-97.
35. Lamprech W, Trautschold I. Adenosine 5'-triphosphate determination with hexokinase and glucose 6-phosphate dehydrogenase. In: Bergmeyer HU, ed. *Methods of Enzymatic Analysis*, New York: Verlag Chemie, Weinheim and Academic Press, 1976; 4:2101-9.
36. Christopher BH, Hani P, Grewal L, *et al.*: Anti-TNF- α therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. *Am J Surg* 1996; 71:274-80.
37. Chan YC, Leung PS. Acute pancreatitis: Animal models and advances in basic research. *Pancreas* 2007; 34:1-14.
38. Dellinger RP, Levy MM, Carlet JM, *et al.*: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: *Crit Care Med* 2008; 36:296-327. Erratum in: *Crit Care Med* 2008; 36:1394-6.
39. Abe R, Shimosegawa T, Kikuchi Y, *et al.*: The role of pituitary-adrenal counterregulation of inflammation in cerulein-induced pancreatitis: A comparison between Fischer and Lewis rats. *Pancreas* 1996; 12:280-5.

40. De Dios I, San Roman JI, Manso M, *et al.*: Glucocorticoids effects on exocrine pancreatic secretion in cerulein-induced acute pancreatitis in the rat. *Arch Int Physiol Biochem* 1990; 98:361-9.
41. Manso MA, Rebollo A, Pescador R, *et al.*: Action of CCK on CDE diet-induced acute pancreatitis in rats treated with hydrocortisone. *Comp Biochem Phys C Pharm Tox Endocr* 1995; 111:257-63.
42. Lazar G Jr, Varga J, Lazar G, *et al.*: The effects of glucocorticoids and a glucocorticoid antagonist (Ru-38486) on experimental acute pancreatitis in rat. *Acta Chir Hung* 1997; 36:190-1.
43. Lazar G Jr, Duda E, Lazar G. Effect of RU-38486 on TNF production and toxicity. *FEBS Lett* 1992; 308:137-40.
44. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. *Am J Surg* 1998; 175:76-83.
45. Tcholakov O, Uhl W, Gloor B, *et al.*: Role of arachidonic acid metabolism and its inhibition by hydrocortisone in experimental acute pancreatitis. *Eur Surg Res* 1999; 31:79-80.
46. Osman MO, Jacobsen NO, Kristensen J, *et al.*: Beneficial effects of hydrocortisone in a model of experimental acute pancreatitis. *Dig Surg* 1999; 16:214-21.
47. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. *Science* 1966; 153:80-2.
48. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. *Proc Natl Acad Sci USA* 1966; 56:72-7.
49. Scheinman RI, Cogswell PC, Lofquist AK, *et al.*: Role of transcriptional activation of I κ B α in mediation of immunosuppression of glucocorticoids. *Science* 1995; 270:283-6.
50. Auphan N, DiDonato JA, Rosette C, *et al.*: Immunosuppression by glucocorticoids: inhibition of NF- κ B activity through induction of I κ B synthesis. *Science* 1995; 270:286-90.
51. Fingerle-Rowson G, Koch P, Bikoff R, *et al.*: Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. *Am J Pathol* 2003; 162:47-56.
52. Lue H, Kleemann R, Calandra T, *et al.*: Macrophage migration inhibitory factor (MIF): mechanism of action and role in disease. *Microbes Infect* 2002; 4:449-60.
53. Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. *J FASEB* 1996; 10:1607-13.
54. Tierney T, Patel R, Stead CA, *et al.*: Macrophage migration inhibitory factor is released from pituitary folliculostellate-like cells by endotoxin and dexamethasone and attenuates the steroid-induced inhibition of interleukin 6 release. *Endocrinology* 2005; 146:35-43.

55. Rahman SH, Menon KV, Holmfield JH, *et al.*: Serum macrophage migration inhibitory factor is an early marker of pancreatic necrosis in acute pancreatitis. *Ann Surg* 2007; 245:282-9.
56. Nagasaki K, Matsumoto K, Kaneda M, *et al.*: Effects of preinjury administration of corticosteroids on pseudointimal hyperplasia and cytokine response in a rat model of balloon aortic injury. *World J Surg* 2004; 28:910-16.
57. Bruhn A, Verdant C, Vercruysse V, *et al.*: Effects of dexamethasone on macrophage migration inhibitory factor production in sepsis. *Shock* 2006; 26:169-73.
58. Maxime V, Fitting C, Annane D, *et al.*: Corticoids normalize leukocyte production of macrophage migration inhibitory factor in septic shock. *J Infect Dis* 2005; 191:138-44.
59. Cao WG, Morin M, Sengers V, *et al.*: Tumour necrosis factor-alpha up-regulates macrophage migration inhibitory factor expression in endometrial stromal cells via the nuclear transcription factor NF-kappa β . *Hum Reprod* 2006; 21:421-8.
60. Shimizu T, Nishihira J, Watanabe H, *et al.*: Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells. *J Biol Chem* 2004; 279:13729-37.
61. Adcock IM, Shirasaki H, Gelder CM, *et al.*: The effect of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. *Life Sci* 1994; 55:1147-53.
62. Scheinman RI, Gualbert A, Jewell CM, *et al.*: Characterization of mechanism involved in transrepression of NF- κ B by activated glucocorticoid receptors. *Mol Cell Biol* 1995; 15:943-53.
63. Barnes PJ, Karin M. Mechanism of disease: Nuclear factor- κ B - A pivotal transcription factor in chronic inflammatory diseases. *New Engl J Med* 1997; 15:1066-71.
64. Vaquero E, Gukovsky I, Zaninovic V, *et al.*: Lokalized pancreatic NF- κ B activation and inflammatory response in taurocholate-induced pancreatitis. *Am J Physiol* 2001; 280:1197-1208.
65. Daun JM, Cannon JG. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic I κ B α . *Am J Phys Reg Int Comp Phys* 2000; 279:1043-49.
66. Marco S, Michael AD, Hans GB. Different changes in high-energy phosphates in alcoholic acute pancreatitis and taurocholate acute pancreatitis in rats using NMR spectroscopy at 2.0 T. *Pancreas* 1997; 15:350-7.
67. Halangk W, Matthias R, Nedelev B, *et al.*: Energy metabolism of pancreatic mitochondria in experimental acute pancreatitis. *Zentralbl Chir* 1997; 122:305-8.

68. Yan L, Kazue O, Nobuaki K. Changes in hepatic energy metabolism in experimental acute pancreatitis. *Chin Med J* 1992; 105:684-8.
69. Takashi U, Hung SH, Steven EA, *et al.*: Pancreatitis-induced ascitic fluid and hepatocellular dysfunction in severe acute pancreatitis. *J Surg Res* 1999; 82:305-11.

8. ANNEX

I.

